Radiant Research Realigns Strategy, Exits the CRO Business


Company News Release

Radiant Research

, a network of clinical trial sites owned and operated by CRA Holdings Inc., has announced the sale of its Contract Research Organization (CRO) division, Radiant Development, to Accelovance. The sale was completed on Friday, March 1st. Based in Chicago, Illinois, Radiant Development is a full service CRO that offers a range of services including medical affairs, site selection, project management, biostatistics, medical writing, clinical monitoring and site management.

Radiant Research was acquired by CRA Holdings Inc. in September 2012. Since that time, the company has worked to refocus Radiant’s efforts on its core business of site services. “As an organization that partners with many CROs, we did not want to compete with customers in our own space,” said Mark S. Hanley, CEO of Clinical Research Advantage and Radiant Research. “Accelovance is a highly respected CRO with a proven track record of excellence. The company’s acquisition of Radiant Development is a perfect fit.”

Clinical Research Advantage, Radiant Research and Accelovance are all leaders in the clinical trials industry with a strong focus on vaccine trials.  Clinical Research Advantage received the award for Best Clinical Trial Site Network last year. “We plan to continue our ongoing relationship with Accelovance by partnering with them to conduct high quality clinical trials,” said Hanley. “By exiting the CRO business, we are able to focus on operating and expanding our site network.”

When CRA Holdings Inc. acquired Radiant Research, it became the largest and most therapeutically diverse clinical trial site network in the country. The companies currently have a combined total of 57 clinical trial sites with aggressive plans for continued site expansion throughout 2013.

Related Links:

Clinical Research Advantage and Radiant Research Form Large/Therapeutically Diverse SMO

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.